Stifel Nicolaus Issues Positive Forecast for Stryker (NYSE:SYK) Stock Price

Stryker (NYSE:SYK) had its price target increased by equities researchers at Stifel Nicolaus from $400.00 to $440.00 in a note issued to investors on Wednesday,Benzinga reports. The brokerage currently has a “buy” rating on the medical technology company’s stock. Stifel Nicolaus’ price objective points to a potential upside of 11.41% from the stock’s current price.

Several other research analysts have also weighed in on SYK. Barclays upped their price target on Stryker from $402.00 to $418.00 and gave the company an “overweight” rating in a research report on Thursday, October 31st. Royal Bank of Canada reissued an “outperform” rating and issued a $425.00 price target on shares of Stryker in a research note on Tuesday, January 7th. JMP Securities reiterated a “market perform” rating on shares of Stryker in a research note on Tuesday, January 7th. UBS Group increased their price target on shares of Stryker from $366.00 to $370.00 and gave the stock a “neutral” rating in a research note on Wednesday, October 30th. Finally, Robert W. Baird lifted their price objective on shares of Stryker from $378.00 to $405.00 and gave the company an “outperform” rating in a research note on Wednesday, October 30th. Five analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to data from MarketBeat, Stryker has an average rating of “Moderate Buy” and a consensus price target of $411.30.

Stryker Stock Down 1.2 %

NYSE:SYK opened at $394.92 on Wednesday. The firm has a market capitalization of $150.55 billion, a price-to-earnings ratio of 42.33, a PEG ratio of 2.68 and a beta of 0.95. Stryker has a 1-year low of $310.74 and a 1-year high of $406.19. The company has a current ratio of 1.91, a quick ratio of 1.22 and a debt-to-equity ratio of 0.66. The business’s fifty day moving average price is $376.44 and its 200 day moving average price is $361.98.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, beating the consensus estimate of $3.87 by $0.14. Stryker had a return on equity of 23.07% and a net margin of 16.34%. During the same quarter last year, the business earned $3.46 EPS. On average, sell-side analysts forecast that Stryker will post 12.06 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO Kevin Lobo sold 57,313 shares of the business’s stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $368.70, for a total transaction of $21,131,303.10. Following the sale, the chief executive officer now owns 100,027 shares of the company’s stock, valued at $36,879,954.90. The trade was a 36.43 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 5.50% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in SYK. Advisory Alpha LLC increased its holdings in Stryker by 20.4% during the second quarter. Advisory Alpha LLC now owns 2,304 shares of the medical technology company’s stock valued at $784,000 after buying an additional 390 shares during the last quarter. Cetera Investment Advisers grew its stake in Stryker by 2.5% during the second quarter. Cetera Investment Advisers now owns 89,948 shares of the medical technology company’s stock valued at $30,605,000 after acquiring an additional 2,220 shares in the last quarter. New Century Financial Group LLC grew its stake in Stryker by 29.5% during the second quarter. New Century Financial Group LLC now owns 798 shares of the medical technology company’s stock valued at $272,000 after acquiring an additional 182 shares in the last quarter. Centennial Bank AR grew its stake in Stryker by 106.7% during the second quarter. Centennial Bank AR now owns 93 shares of the medical technology company’s stock valued at $32,000 after acquiring an additional 48 shares in the last quarter. Finally, Clear Rock Advisors LLC grew its stake in shares of Stryker by 1.4% in the 2nd quarter. Clear Rock Advisors LLC now owns 10,426 shares of the medical technology company’s stock worth $3,547,000 after buying an additional 140 shares in the last quarter. 77.09% of the stock is owned by hedge funds and other institutional investors.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.